靜脈注射免疫球蛋白市場規模、佔有率和成長分析（按產品、通路、應用和地區分類）－2026-2033年產業預測

預計到 2024 年，靜脈注射免疫球蛋白市場規模將達到 138.4 億美元，到 2025 年將達到 148.5 億美元，到 2033 年將達到 261 億美元，預測期（2026-2033 年）的複合年成長率為 7.3%。

靜脈注射免疫球蛋白（IVIG）市場正經歷顯著成長，這主要受多種因素影響，包括人口老化和免疫不全症盛行率上升。 IVIG療法的廣泛應用及其仿單標示外用藥進一步推動了市場需求。慢性脫髓鞘多發性神經炎（CIDP）及相關出血性疾病患者數量的顯著增加也強化了這一趨勢。此外，醫療保健投資的不斷成長也推動了該市場的發展。自體免疫疾病和其他各種疾病發病率的上升也在塑造IVIG市場格局中發揮關鍵作用，凸顯了該產品在滿足多樣化醫療需求和應對複雜免疫健康挑戰方面的重要作用。

靜脈注射免疫球蛋白市場促進因素

靜脈注射免疫球蛋白療法作為多種罕見免疫和神經系統疾病（尤其是原發性免疫力缺乏及相關疾病）的主要治療方法，日益普及是推動市場成長的關鍵因素。靜脈注射免疫球蛋白療法作為主要治療方案的廣泛認可，凸顯了其在應對這些複雜健康問題方面的有效性和重要性。隨著越來越多的醫療服務提供者和患者認知到該治療方法的益處，對靜脈注射免疫球蛋白的需求持續成長，進一步鞏固了其在治療這些棘手疾病中的作用，並推動了市場的發展。

限制靜脈注射免疫球蛋白市場的因素

診斷和治療去髓鞘化疾病帶來的經濟負擔對靜脈注射免疫球蛋白（IVIG）市場構成重大挑戰。尤其令人擔憂的是IVIG治療費用不斷上漲，因為這種治療通常需要每隔幾週進行一次定期靜脈輸注，一年內可能需要多次治療。 IVIG的平均成本估計約為每克73.89美元，累積費用可能高達每年約1萬美元。如此高昂的費用嚴重阻礙了市場成長，限制了需要這種重要治療以有效控制病情的患者獲得治療的機會。

靜脈注射免疫球蛋白市場趨勢

靜脈注射免疫球蛋白（IVIG）市場正經歷著動態變革，其成長潛力正受到關鍵趨勢的驅動。其中一個顯著趨勢是IVIG在神經系統疾病治療中的應用日益廣泛，這標誌著其應用範圍正從傳統用途擴展到更廣泛的領域。此外，將個人化醫療概念融入IVIG療法標誌著一個變革性的轉折點，使得針對個別患者情況的客製化治療成為可能。同時，創新免疫調節療法的興起正在重塑市場格局，拓展治療可能性，改善患者預後，進而推動IVIG產品的整體需求與發展。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球靜脈注射免疫球蛋白市場規模（按產品和複合年成長率分類）（2026-2033 年）

• IGG
• IGA
• IGM
• IGE
• IGD

全球靜脈注射免疫球蛋白市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 專科藥房
• 其他

全球靜脈注射免疫球蛋白市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 免疫力缺乏
• CIDP
• 低丙種球蛋白血症
• 先天性愛滋病
• 慢性淋巴性白血病
• 重症肌無力
• 多灶性運動神經病變
• ITP
• 川崎病
• Guillain-Barré二氏症候群
• 其他

全球靜脈注射免疫球蛋白市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• CSL Behring（Australia）
• Grifols, SA（Spain）
• Octapharma AG（Switzerland）
• Kedrion SpA（Italy）
• Bio Products Laboratory Ltd.（United Kingdom）
• Biotest AG（Germany）
• China Biologic Products Holdings, Inc.（China）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• ADMA Biologics, Inc.（United States）
• Sanquin Blood Supply Foundation（Netherlands）
• Kamada Ltd.（Israel）
• Emergent BioSolutions Inc.（United States）
• Hualan Biological Engineering Inc.（China）
• Green Cross Corporation（South Korea）
• Bharat Serums and Vaccines Limited（India）
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.（China）
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd.（China）
• Nanjing Xinbai Pharmaceutical Co., Ltd.（China）

結論與建議

Intravenous Immunoglobulin Market size was valued at USD 13.84 Billion in 2024 and is poised to grow from USD 14.85 Billion in 2025 to USD 26.1 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The intravenous immunoglobulin (IVIG) market is experiencing significant growth driven by a range of factors, including an increasing aging population and a rise in immunodeficiency disorders. The broader acceptance of IVIG treatments and their application for off-label uses further enhance market demand. A notable rise in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and associated bleeding issues intensifies this trend. Additionally, heightened healthcare investments are fostering this market's evolution. The increasing incidence of autoimmune diseases and various other pathological conditions also plays a crucial role in shaping the IVIG landscape, emphasizing the product's integral function in meeting diverse medical requirements and addressing the complexities of immunological health challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Immunoglobulin Market Segments Analysis

Global Intravenous Immunoglobulin Market is segmented by Product, Distribution Channel, Application and region. Based on Product, the market is segmented into IGG, IGA, IGM, IGE and IGD. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Other. Based on Application, the market is segmented into Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Immunoglobulin Market

The growing adoption of intravenous immunoglobulin therapy as the primary treatment for a variety of rare immunological and neurological disorders, particularly primary immunodeficiency and related diseases, serves as a crucial factor driving the intravenous immunoglobulin market's growth. This widespread recognition of IVIG therapy as a leading option highlights its effectiveness and importance in addressing these complex health issues. As more healthcare providers and patients acknowledge the benefits of this treatment, the demand for intravenous immunoglobulin continues to rise, further solidifying its role in managing these challenging conditions and supporting market advancement.

Restraints in the Intravenous Immunoglobulin Market

The financial strain associated with diagnosing and treating demyelinating diseases poses a substantial challenge for the intravenous immunoglobulin market. The escalating costs associated with IVIG therapy are particularly concerning, as this treatment typically requires regular infusions every few weeks, leading to multiple sessions throughout the year. With the average cost of IVIG estimated at approximately USD 73.89 per gram, the cumulative expenses can reach around USD 10,000 annually. Such high costs serve as a significant obstacle to market growth, limiting accessibility for patients who need this essential therapy for managing their conditions effectively.

Market Trends of the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is experiencing a robust evolution driven by key trends that are redefining its growth potential. One prominent trend is the increasing adoption of IVIG for treating neurological disorders, which signifies a broadening of its applications beyond its conventional uses. Furthermore, the incorporation of personalized medicine into IVIG therapy represents a transformative shift, enabling more customized treatments tailored to individual patient profiles. Additionally, the rise of innovative immunomodulatory therapies is reshaping the market landscape, expanding therapeutic possibilities and enhancing patient outcomes, thereby propelling the overall demand and development of IVIG products.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Immunoglobulin Market Size by Product & CAGR (2026-2033)

• Market Overview
• IGG
• IGA
• IGM
• IGE
• IGD

Global Intravenous Immunoglobulin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Other

Global Intravenous Immunoglobulin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

Global Intravenous Immunoglobulin Market Size & CAGR (2026-2033)

• North America (Product, Distribution Channel, Application)
  • US
  • Canada
• Europe (Product, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Blood Supply Foundation (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanjing Xinbai Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations